ClinicalTrials.gg
CompletedNCT02912260Updated Dec 23, 2025Results posted

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of MGL-3196 and Placebo in Non-alcoholic Steatohepatitis, sponsored by Madrigal Pharmaceuticals, Inc.. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
127th of 460
125 · median 56
Started
2016
with 27 others
Phase 2
192 of 547
15 open now
Registered
188th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 127th largest by enrollment of the 460 interventional ones that give a count, is one of 28 that started in 2016, is one of 192 in phase 2, and was the 188th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).

03

Conditions studied

  • Non-alcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria. Participants who meet all of the following criteria will be eligible to participate in the study:

  • Must be willing to participate in the study and provide written ;
  • Male and female adults ≥18 years of age;
  • Female participants of child bearing potential with negative serum pregnancy (beta human chorionic gonadotropin) tests who are not breastfeeding, do not plan to become pregnant during the study, and agree to use effective (that is, condoms, diaphragm, nonhormonal intrauterine device [IUD], or sexual abstinence [only if this is in line with the participant's current lifestyle]) throughout the study and for at least 1 month after study completion; hormonal contraception (estrogens stable ≥3 months) and hormonal IUDs are permitted if used with a secondary birth control measure (for example, condoms); or female participants of non-child bearing potential (that is, surgically [bilateral oophorectomy, hysterectomy, or tubal ligation] or naturally sterile [>12 consecutive months without menses]); Male participants who have sexual intercourse with a female partner of child bearing potential from the first dose of study drug until 1 month after study completion must be either surgically sterile (confirmed by documented azoospermia >90 days after the procedure) or agree to use a condom with spermicide. All male participants must agree not to donate sperm from the first dose of study drug until 1 month after study completion;
  • Must have confirmation of ≥10% liver fat content on magnetic resonance imaging proton density fat fraction;
  • -proven NASH. Must have had prior liver biopsy within 180 days of randomization with fibrosis stage 1 to 3 and a non-alcoholic fatty liver disease activity score (NAS) of ≥4 with a score of 1 or more in each of the following NAS components:

    • Steatosis (scored 0 to 3),
    • Ballooning degeneration (scored 0 to 2), and
    • Lobular inflammation (scored 0 to 3);
  • Must have documented historical (3 weeks to 6 months prior to the study entry) (ALT) and aspartate aminotransferase (AST) levels consistent with the screening ALT and AST values.

Exclusion Criteria. Participants who meet any of the following criteria will be excluded from participation in the study:

Note: Unless otherwise specified, repeat testing may be performed in consultation with the Medical Monitor.

  • History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening;
  • Hyperthyroidism;
  • Participants on thyroid replacement therapy (with exceptions);
  • Prior or planned (during the study period) bariatric surgery (for example, gastroplasty, roux-en-Y gastric bypass);
  • Type 1 diabetes;
  • Uncontrolled Type 2 diabetes defined as (HbA1c) ≥ 9.5% at screening (participants with HbA1c ≥ 9.5% may be rescreened);
  • Use of obeticholic acid, ursodeoxycholic acid (Ursodiol® and Urso®), high dose vitamin E (>400 IU/day) unless on stable dose of vitamin E >400 IU/day for at least 6 months at the time of liver biopsy, or pioglitazone within 90 days prior to enrollment or since screening biopsy, whichever is longer;
  • Presence of cirrhosis on liver biopsy (stage 4 fibrosis);
  • count \< 140,000/mm\^3;
  • Clinical evidence of hepatic decompensation;
  • Evidence of other forms of chronic liver disease;
  • Active, serious medical disease with likely \<2 years;
  • Participation in an new drug trial in the 30 days prior to randomization; or
  • Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the participant, or interfere with the study outcomes.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    MGL-3196

    Study Drug

    Drug: MGL-3196

  • Placebo comparator
    Placebo

    Matching Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)

    The primary endpoint was relative change in MRI-PDFF assessed hepatic fat fraction compared with placebo at Week 12 in participants who had both a baseline and Week 12 MRI-PDFF. Least squares (LS) mean was provided for the statistical comparison of MGL-3196 versus placebo.

    Time frame: Week 12

Secondary outcomes

  1. Percentage Of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Week 12 and Week 36

  2. Percent Change From Baseline To Week 36 In Hepatic Fat Fraction Assessed By MRI-PDFF

    The endpoint was relative change assessed hepatic fat fraction compared with placebo at Week 36. LS mean was provided for the statistical comparison of MGL-3196 versus placebo.

    Time frame: Week 36

  3. Change From Baseline To Week 12 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF

    The endpoint was change in MRI-PDFF assessed absolute hepatic fat fraction compared with placebo at Week 12. LS mean was provided for the comparison of MGL-3196 versus placebo.

    Time frame: Week 12

  4. Change From Baseline To Week 36 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF

    The endpoint was change in assessed absolute hepatic fat fraction compared with placebo at Week 36. LS mean was provided for the comparison of MGL-3196 versus placebo.

    Time frame: Week 36

  5. Percentage Of Participants With At Least 30% Relative Fat Reduction at Week 12

    The endpoint presented the percentage of participants achieving a relative fat reduction of ≥30% at Week 12.

    Time frame: Week 12

  6. Percentage Of Participants With At Least 30% Relative Fat Reduction At Week 36

    The endpoint presented the percentage of participants achieving a relative fat reduction of ≥30% at Week 36.

    Time frame: Week 36

  7. Percentage Of Participants Achieving A 1-Point Reduction In Non-alcoholic Fatty Liver Disease Activity Score (NAS) At Week 36

    The NAS is a histologic scale for non-alcoholic steatohepatitis (NASH) activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 1-point or greater reduction in NAS.

    Time frame: Week 36

  8. Percentage Of Participants Achieving A 2-Point Reduction In NAS At Week 36

    The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS.

    Time frame: Week 36

  9. Percentage Of Participants Achieving A 2-Point Reduction In NAS And Either A ≥1-Point Reduction In Lobular Inflammation Or Hepatocellular Ballooning At Week 36

    The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS and a 1-point or greater reduction in lobular inflammation or hepatocellular ballooning.

    Time frame: Week 36

  10. Percentage Of Participants Achieving A 2-Point Reduction In NAS Without Fibrosis Worsening At Week 36

    The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). Fibrosis stage (0 to 3) was also included in the assessment. The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS without worsening fibrosis.

    Time frame: Week 36

  11. Percentage Of Participants With A Reduction In Hepatocellular Steatosis At Week 36

    The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in hepatocellular steatosis.

    Time frame: Week 36

  12. Percentage Of Participants With A Reduction In Lobular Inflammation At Week 36

    The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in lobular inflammation.

    Time frame: Week 36

  13. Percentage Of Participants With A Reduction In Hepatocellular Ballooning At Week 36

    The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in hepatocellular ballooning.

    Time frame: Week 36

  14. Percentage Of Participants Achieving NASH Resolution With At Least 2-Point Reduction In NAS At Week 36

    The endpoint presented the percentage of participants achieving NASH resolution with a 2-point reduction at Week 36.

    Time frame: Week 36

  15. Percent Change From Baseline To Week 12 In High-sensitivity C-reactive Protein (hsCRP)

    hsCRP was used as a non-invasive inflammation marker for this study. Blood samples were collected to determine the effect of MGL-3196 on hsCRP.

    Time frame: Week 12

  16. Percent Change From Baseline To Week 36 In hsCRP

    hsCRP was used as a non-invasive inflammation marker for this study. Blood samples were collected to determine the effect of MGL-3196 on hsCRP.

    Time frame: Week 36

  17. Change From Baseline To Week 12 In Serum Alanine Aminotransferase (ALT)

    Blood samples were collected to determine the effect of MGL-3196 on serum ALT.

    Time frame: Week 12

  18. Change From Baseline To Week 36 In ALT

    Blood samples were collected to determine the effect of MGL-3196 on serum ALT.

    Time frame: Week 36

  19. Change From Baseline To Week 12 In Serum Aspartate Aminotransferase (AST)

    Blood samples were collected to determine the effect of MGL-3196 on serum AST.

    Time frame: Week 12

  20. Change From Baseline To Week 36 In AST

    Blood samples were collected to determine the effect of MGL-3196 on serum AST.

    Time frame: Week 36

  21. Percent Change From Baseline To Week 12 In Lipid Parameters

    Blood samples were collected to determine the effect of MGL-3196 on lipid parameters including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol (TC), triglycerides (TG), apolipoprotein B (ApoB), and Apolipoprotein CIII (ApoCIII).

    Time frame: Week 12

  22. Percent Change From Baseline To Week 36 In Lipid Parameters

    Blood samples were collected to determine the effect of MGL-3196 on lipid parameters including LDL-C, HDL-C, non-HDL-C, TC, TG, ApoB, and ApoCIII.

    Time frame: Week 36

  23. Percent Change From Baseline To Week 12 In Lipid Parameter Lipoprotein(a) (Lp[a])

    Blood samples were collected to determine the effect of MGL-3196 on lipid parameter Lp(a).

    Time frame: Week 12

  24. Percent Change From Baseline To Week 36 In Lipid Parameter Lp[a]

    Blood samples were collected to determine the effect of MGL-3196 on lipid parameter Lp(a).

    Time frame: Week 36

  25. Change From Baseline To Week 12 And Week 36 In Cytokeratin-18 (CK-18)

    Serum CK-18 fragments, detected using the M30 antibody, is a non-invasive biomarker for NASH that may reflect hepatocyte apoptosis.

    Time frame: Week 12 and Week 36

  26. Change From Baseline To Week 12 And Week 36 In Enhanced Liver Fibrosis (ELF) Test

    The ELF Test is a non-invasive blood test that provides a simple, unitless numeric score that is used as a marker of collagen formation and fibrogenic activity and can be used to assess the risk of progression to cirrhosis. Scores below 9.8 indicate low risk of disease progression, and scores above 11.29 indicate high risk. The ELF score is derived from values of three serum biomarkers: hyaluronic acid (HA), procollagen III N-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1). The formula is 2.278 + 0.851 × ln(HA) + 0.751 × ln(PIIINP) + 0.394 × ln(TIMP-1); there are no minimum or maximum values.

    Time frame: Week 12 and Week 36

  27. Change From Baseline To Week 12 And Week 36 In Fibrosis-4 (Fib-4) Score

    The Fib-4 score is a scoring system used to estimate the amount of scarring in the liver. It is based on common clinical parameters (age, AST, ALT, and platelets) and has been shown to have the best diagnostic accuracy for advanced fibrosis when compared with other noninvasive clinical scores. Scores are categorized into low (\<1.30), indeterminate (1.30-2.67), or high (\>2.67) risk of fibrosis. The formula for Fib-4 is: (Age \[yr\] x AST \[U/L\]) / ((PLT \[109/L\]) x (ALT \[U/L\])½); there are no minimum or maximum values

    Time frame: Week 12 and Week 36

  28. Change From Baseline of Thyrotropin at Week 12

    Thyrotropin (TSH) was assessed at each study visit.

    Time frame: Baseline up to Week 12

  29. Change From Baseline of Total Thyroxine at Week 12

    Total thyroxine (FT4) was assessed at each study visit.

    Time frame: Baseline up to Week 12

  30. Change From Baseline of Free Thyroxine at Week 12

    Free thyroxine (FT4) was assessed at each study visit.

    Time frame: Baseline up to Week 12

  31. Change From Baseline of Total Triiodothyronine at Week 12

    Total Triiodothyronine (T3) was assessed at each study visit.

    Time frame: Baseline up to Week 12

  32. Change From Baseline of Free Triiodothyronine at Week 12

    Free triiodothyronine (T3) was assessed at each study visit.

    Time frame: Baseline up to Week 12

  33. Change From Baseline of Thyroxine Binding Globulin at Week 12

    Thyroxine Binding Globulin was assessed at each study visit.

    Time frame: Baseline up to Week 12

  34. Change From Baseline of Reverse Triiodothyronine Globulin at Week 12

    Reverse Triiodothyronine (T3) was assessed at each study visit.

    Time frame: Baseline up to Week 12

  35. Change From Baseline of Thyrotropin at Week 36

    Tyrotropin (TSH) was assessed at each study visit.

    Time frame: Baseline up to Week 36

  36. Change From Baseline of Total Thyroxine at Week 36

    Total thyroxine (FT4), thyrotropin (TSH) was assessed at each study visit.

    Time frame: Baseline up to Week 36

  37. Change From Baseline of Free Thyroxine Week 36

    Total free thyroxine (FT4) was assessed at each study visit.

    Time frame: Baseline up to Week 36

  38. Change From Baseline of Total Triiodothyronine at Week 36

    Total triiodothyronine (T3) was assessed at each study visit.

    Time frame: Baseline up to Week 36

  39. Change From Baseline of Free Triiodothyronine at Week 36

    Free triiodothyronine (T3) was assessed at each study visit.

    Time frame: Baseline up to Week 36

  40. Change From Baseline of Thyroxine-Binding Globulin at Week 36

    Thyroxine-binding globulin (TBG) was assessed at each study visit.

    Time frame: Baseline up to Week 36

  41. Change From Baseline of Reverse Triiodothyronine at Week 36

    Reverse triiodothyronine (T3) was assessed at each study visit.

    Time frame: Baseline up to Week 36

07

Results

Posted Dec 23, 2025

Participant flow

Participants underwent screening procedures within 42 days of randomization. To participate in the study, participants were required to have had a qualifying liver biopsy within 180 days of randomization.

Main Study
Participant flow — Main Study
MilestoneMGL-3196Placebo
Started8441
Received at least 1 dose of study drug8441
Completed7434
Not completed107
Withdrew: Lost to follow-up54
Withdrew: Withdrawal by subject22
Withdrew: Adverse event30
Withdrew: Physician decision01
Extension Study
Participant flow — Extension Study
MilestoneMGL-3196Placebo
Started1714
Completed1613
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryPercent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)

The primary endpoint was relative change in MRI-PDFF assessed hepatic fat fraction compared with placebo at Week 12 in participants who had both a baseline and Week 12 MRI-PDFF. Least squares (LS) mean was provided for the statistical comparison of MGL-3196 versus placebo.

Time frame:
Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)
percent changeMGL-3196Placebo
Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)-32.9 ± 3.0-10.4 ± 4.3
Statistical analysis
  • MGL-3196 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): -22.5 · 95% CI -32.9 to -12.2
SecondaryPercentage Of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Week 12 and Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants With Adverse Events (AEs)
percentage of participantsMGL-3196Placebo
Week 1271.446.3
Week 3686.968.3
SecondaryPercent Change From Baseline To Week 36 In Hepatic Fat Fraction Assessed By MRI-PDFF

The endpoint was relative change assessed hepatic fat fraction compared with placebo at Week 36. LS mean was provided for the statistical comparison of MGL-3196 versus placebo.

Time frame:
Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline To Week 36 In Hepatic Fat Fraction Assessed By MRI-PDFF
percent changeMGL-3196Placebo
Percent Change From Baseline To Week 36 In Hepatic Fat Fraction Assessed By MRI-PDFF-37.3 ± 3.7-8.9 ± 5.4
Statistical analysis
  • MGL-3196 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): -28.4 · 95% CI -41.3 to -15.4
SecondaryChange From Baseline To Week 12 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF

The endpoint was change in MRI-PDFF assessed absolute hepatic fat fraction compared with placebo at Week 12. LS mean was provided for the comparison of MGL-3196 versus placebo.

Time frame:
Week 12
Reported as:
Least squares mean · percentage
Change From Baseline To Week 12 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF
percentageMGL-3196Placebo
Change From Baseline To Week 12 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF-7.0 ± 0.6-2.7 ± 0.8
Statistical analysis
  • MGL-3196 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): -4.3 · 95% CI -6.3 to -2.4
SecondaryChange From Baseline To Week 36 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF

The endpoint was change in assessed absolute hepatic fat fraction compared with placebo at Week 36. LS mean was provided for the comparison of MGL-3196 versus placebo.

Time frame:
Week 36
Reported as:
Least squares mean · percentage
Change From Baseline To Week 36 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF
percentageMGL-3196Placebo
Change From Baseline To Week 36 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF-8.2 ± 0.7-2.9 ± 1.0
Statistical analysis
  • MGL-3196 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): -5.3 · 95% CI -7.8 to -2.8
SecondaryPercentage Of Participants With At Least 30% Relative Fat Reduction at Week 12

The endpoint presented the percentage of participants achieving a relative fat reduction of ≥30% at Week 12.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage Of Participants With At Least 30% Relative Fat Reduction at Week 12
percentage of participantsMGL-3196Placebo
Percentage Of Participants With At Least 30% Relative Fat Reduction at Week 1260.318.4
SecondaryPercentage Of Participants With At Least 30% Relative Fat Reduction At Week 36

The endpoint presented the percentage of participants achieving a relative fat reduction of ≥30% at Week 36.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants With At Least 30% Relative Fat Reduction At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants With At Least 30% Relative Fat Reduction At Week 3667.629.4
SecondaryPercentage Of Participants Achieving A 1-Point Reduction In Non-alcoholic Fatty Liver Disease Activity Score (NAS) At Week 36

The NAS is a histologic scale for non-alcoholic steatohepatitis (NASH) activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 1-point or greater reduction in NAS.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants Achieving A 1-Point Reduction In Non-alcoholic Fatty Liver Disease Activity Score (NAS) At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants Achieving A 1-Point Reduction In Non-alcoholic Fatty Liver Disease Activity Score (NAS) At Week 3676.764.7
SecondaryPercentage Of Participants Achieving A 2-Point Reduction In NAS At Week 36

The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants Achieving A 2-Point Reduction In NAS At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants Achieving A 2-Point Reduction In NAS At Week 3656.232.4
SecondaryPercentage Of Participants Achieving A 2-Point Reduction In NAS And Either A ≥1-Point Reduction In Lobular Inflammation Or Hepatocellular Ballooning At Week 36

The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS and a 1-point or greater reduction in lobular inflammation or hepatocellular ballooning.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants Achieving A 2-Point Reduction In NAS And Either A ≥1-Point Reduction In Lobular Inflammation Or Hepatocellular Ballooning At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants Achieving A 2-Point Reduction In NAS And Either A ≥1-Point Reduction In Lobular Inflammation Or Hepatocellular Ballooning At Week 3650.732.4
SecondaryPercentage Of Participants Achieving A 2-Point Reduction In NAS Without Fibrosis Worsening At Week 36

The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). Fibrosis stage (0 to 3) was also included in the assessment. The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS without worsening fibrosis.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants Achieving A 2-Point Reduction In NAS Without Fibrosis Worsening At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants Achieving A 2-Point Reduction In NAS Without Fibrosis Worsening At Week 3645.232.4
SecondaryPercentage Of Participants With A Reduction In Hepatocellular Steatosis At Week 36

The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in hepatocellular steatosis.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants With A Reduction In Hepatocellular Steatosis At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants With A Reduction In Hepatocellular Steatosis At Week 3661.644.1
SecondaryPercentage Of Participants With A Reduction In Lobular Inflammation At Week 36

The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in lobular inflammation.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants With A Reduction In Lobular Inflammation At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants With A Reduction In Lobular Inflammation At Week 3621.917.6
SecondaryPercentage Of Participants With A Reduction In Hepatocellular Ballooning At Week 36

The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in hepatocellular ballooning.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants With A Reduction In Hepatocellular Ballooning At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants With A Reduction In Hepatocellular Ballooning At Week 3658.958.8
SecondaryPercentage Of Participants Achieving NASH Resolution With At Least 2-Point Reduction In NAS At Week 36

The endpoint presented the percentage of participants achieving NASH resolution with a 2-point reduction at Week 36.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage Of Participants Achieving NASH Resolution With At Least 2-Point Reduction In NAS At Week 36
percentage of participantsMGL-3196Placebo
Percentage Of Participants Achieving NASH Resolution With At Least 2-Point Reduction In NAS At Week 3627.414.7
SecondaryPercent Change From Baseline To Week 12 In High-sensitivity C-reactive Protein (hsCRP)

hsCRP was used as a non-invasive inflammation marker for this study. Blood samples were collected to determine the effect of MGL-3196 on hsCRP.

Time frame:
Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline To Week 12 In High-sensitivity C-reactive Protein (hsCRP)
percent changeMGL-3196Placebo
Percent Change From Baseline To Week 12 In High-sensitivity C-reactive Protein (hsCRP)29.3 ± 18.3613.2 ± 25.97
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.6155 · Mean difference (net): 16.0 · 95% CI -47.0 to 79.0
SecondaryPercent Change From Baseline To Week 36 In hsCRP

hsCRP was used as a non-invasive inflammation marker for this study. Blood samples were collected to determine the effect of MGL-3196 on hsCRP.

Time frame:
Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline To Week 36 In hsCRP
percent changeMGL-3196Placebo
Percent Change From Baseline To Week 36 In hsCRP90.9 ± 67.5234.0 ± 96.88
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.6311 · Mean difference (net): 56.9 · 95% CI -177.4 to 291.1
SecondaryChange From Baseline To Week 12 In Serum Alanine Aminotransferase (ALT)

Blood samples were collected to determine the effect of MGL-3196 on serum ALT.

Time frame:
Week 12
Reported as:
Least squares mean · IU/L
Change From Baseline To Week 12 In Serum Alanine Aminotransferase (ALT)
IU/LMGL-3196Placebo
Change From Baseline To Week 12 In Serum Alanine Aminotransferase (ALT)-8.2 ± 2.7-5.2 ± 3.9
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.5260 · Mean difference (net): -3.0 · 95% CI -12.4 to 6.4
SecondaryChange From Baseline To Week 36 In ALT

Blood samples were collected to determine the effect of MGL-3196 on serum ALT.

Time frame:
Week 36
Reported as:
Least squares mean · IU/L
Change From Baseline To Week 36 In ALT
IU/LMGL-3196Placebo
Change From Baseline To Week 36 In ALT-15.4 ± 4.711.0 ± 6.8
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.0019 · Mean difference (net): -26.4 · 95% CI -42.8 to -9.9
SecondaryChange From Baseline To Week 12 In Serum Aspartate Aminotransferase (AST)

Blood samples were collected to determine the effect of MGL-3196 on serum AST.

Time frame:
Week 12
Reported as:
Least squares mean · IU/L
Change From Baseline To Week 12 In Serum Aspartate Aminotransferase (AST)
IU/LMGL-3196Placebo
Change From Baseline To Week 12 In Serum Aspartate Aminotransferase (AST)-5.8 ± 1.8-1.1 ± 2.5
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.1275 · Mean difference (net): -4.8 · 95% CI -10.9 to 1.4
SecondaryChange From Baseline To Week 36 In AST

Blood samples were collected to determine the effect of MGL-3196 on serum AST.

Time frame:
Week 36
Reported as:
Least squares mean · IU/L
Change From Baseline To Week 36 In AST
IU/LMGL-3196Placebo
Change From Baseline To Week 36 In AST-7.4 ± 1.93.6 ± 2.8
Statistical analysis
  • MGL-3196 · Linear model · p = 0.0016 · Mean difference (net): -11.1 · 95% CI -17.8 to -4.3
SecondaryPercent Change From Baseline To Week 12 In Lipid Parameters

Blood samples were collected to determine the effect of MGL-3196 on lipid parameters including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol (TC), triglycerides (TG), apolipoprotein B (ApoB), and Apolipoprotein CIII (ApoCIII).

Time frame:
Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline To Week 12 In Lipid Parameters
percent changeMGL-3196Placebo
LDL-C-10.6 ± 1.962.2 ± 2.79
HDL-C5.0 ± 1.911.8 ± 2.72
non-HDL-C-12.1 ± 1.741.2 ± 2.47
TC-8.7 ± 1.370.9 ± 1.95
TG-6.8 ± 4.239.8 ± 6.01
ApoB-14.5 ± 1.590.8 ± 2.25
ApoCIII-9.1 ± 3.238.7 ± 4.62
Lp(a)-8.6 ± 7.5412.3 ± 10.67
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.0002 · Mean difference (net): -12.9 · 95% CI -19.6 to -6.1
  • MGL-3196 vs Placebo · Linear model · p = 0.3388 · Mean difference (net): 3.2 · 95% CI -3.4 to 9.8
  • MGL-3196 vs Placebo · Linear model · p = <0.0001 · Mean difference (net): -13.4 · 95% CI -19.3 to -7.4
  • MGL-3196 vs Placebo · Linear model · p = 0.0001 · Mean difference (net): -9.6 · 95% CI -14.3 to -4.9
  • MGL-3196 vs Placebo · Linear model · p = 0.0258 · Mean difference (net): -16.6 · 95% CI -31.2 to -2.0
  • MGL-3196 vs Placebo · Linear model · p = <0.0001 · Mean difference (net): -15.3 · 95% CI -20.8 to -9.9
  • MGL-3196 vs Placebo · Linear model · p = 0.0021 · Mean difference (net): -17.8 · 95% CI -28.9 to -6.6
  • MGL-3196 vs Placebo · ANOVA · p = 0.1123 · Mean difference (net): -20.9 · 95% CI -46.8 to 5.0
SecondaryPercent Change From Baseline To Week 36 In Lipid Parameters

Blood samples were collected to determine the effect of MGL-3196 on lipid parameters including LDL-C, HDL-C, non-HDL-C, TC, TG, ApoB, and ApoCIII.

Time frame:
Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline To Week 36 In Lipid Parameters
percent changeMGL-3196Placebo
LDL-C-11.0 ± 2.141.5 ± 3.11
HDL-C10.5 ± 3.7212.0 ± 5.41
non-HDL-C-14.0 ± 1.902.1 ± 2.76
TC-8.9 ± 1.613.6 ± 2.34
TG-19.8 ± 4.2917.5 ± 6.24
ApoB-16.5 ± 1.790.9 ± 2.58
ApoCIII-12.0 ± 3.7224.5 ± 5.42
Lp(a)19.0 ± 10.9539.0 ± 15.82
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.0013 · Mean difference (net): -12.4 · 95% CI -19.9 to -5.0
  • MGL-3196 vs Placebo · Linear model · p = 0.8213 · Mean difference (net): -1.5 · 95% CI -14.5 to 11.5
  • MGL-3196 vs Placebo · Linear model · p = <0.0001 · Mean difference (net): -16.1 · 95% CI -22.7 to -9.4
  • MGL-3196 vs Placebo · Linear model · p = <0.0001 · Mean difference (net): -12.5 · 95% CI -18.1 to -6.9
  • MGL-3196 vs Placebo · Linear model · p = <0.0001 · Mean difference (net): -37.3 · 95% CI -52.3 to -22.3
  • MGL-3196 vs Placebo · Linear model · p = <0.0001 · Mean difference (net): -17.4 · 95% CI -23.6 to -11.2
  • MGL-3196 vs Placebo · Linear model · p = <0.0001 · Mean difference (net): -36.5 · 95% CI -49.6 to -23.5
  • MGL-3196 vs Placebo · ANOVA · p = 0.3008 · Mean difference (net): -20.0 · 95% CI -58.2 to 18.2
SecondaryPercent Change From Baseline To Week 12 In Lipid Parameter Lipoprotein(a) (Lp[a])

Blood samples were collected to determine the effect of MGL-3196 on lipid parameter Lp(a).

Time frame:
Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline To Week 12 In Lipid Parameter Lipoprotein(a) (Lp[a])
percent changeMGL-3196Placebo
Percent Change From Baseline To Week 12 In Lipid Parameter Lipoprotein(a) (Lp[a])-8.6 ± 7.5412.3 ± 10.67
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.1123 · Mean difference (net): -20.9 · 95% CI -46.8 to 5.0
SecondaryPercent Change From Baseline To Week 36 In Lipid Parameter Lp[a]

Blood samples were collected to determine the effect of MGL-3196 on lipid parameter Lp(a).

Time frame:
Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline To Week 36 In Lipid Parameter Lp[a]
percent changeMGL-3196Placebo
Percent Change From Baseline To Week 36 In Lipid Parameter Lp[a]19.0 ± 10.9539.0 ± 15.82
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.3008 · Mean difference (net): -20.0 · 95% CI -58.2 to 18.2
SecondaryChange From Baseline To Week 12 And Week 36 In Cytokeratin-18 (CK-18)

Serum CK-18 fragments, detected using the M30 antibody, is a non-invasive biomarker for NASH that may reflect hepatocyte apoptosis.

Time frame:
Week 12 and Week 36
Reported as:
Least squares mean · U/L
Change From Baseline To Week 12 And Week 36 In Cytokeratin-18 (CK-18)
U/LMGL-3196Placebo
Week 12-146.2 ± 35-87.5 ± 51
Week 36-272.0 ± 33-101.0 ± 47
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.3419 · Mean difference (net): -58.75 · 95% CI -180.70 to 63.21
  • MGL-3196 vs Placebo · Linear model · p = 0.0035 · Mean difference (net): -171.24 · 95% CI -285.06 to -57.42
SecondaryChange From Baseline To Week 12 And Week 36 In Enhanced Liver Fibrosis (ELF) Test

The ELF Test is a non-invasive blood test that provides a simple, unitless numeric score that is used as a marker of collagen formation and fibrogenic activity and can be used to assess the risk of progression to cirrhosis. Scores below 9.8 indicate low risk of disease progression, and scores above 11.29 indicate high risk. The ELF score is derived from values of three serum biomarkers: hyaluronic acid (HA), procollagen III N-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1). The formula is 2.278 + 0.851 × ln(HA) + 0.751 × ln(PIIINP) + 0.394 × ln(TIMP-1); there are no minimum or maximum values.

Time frame:
Week 12 and Week 36
Reported as:
Least squares mean · score on a scale
Change From Baseline To Week 12 And Week 36 In Enhanced Liver Fibrosis (ELF) Test
score on a scaleMGL-3196Placebo
Week 12-0.38 ± 0.09-0.02 ± 0.12
Week 36-0.66 ± 0.12-0.18 ± 0.16
Statistical analysis
  • MGL-3196 vs Placebo · Linear model · p = 0.0089 · Mean difference (net): -0.395 · 95% CI -0.686 to -0.103
  • MGL-3196 vs Placebo · Linear model · p = 0.0174 · Mean difference (net): -0.484 · 95% CI -0.879 to -0.088
SecondaryChange From Baseline To Week 12 And Week 36 In Fibrosis-4 (Fib-4) Score

The Fib-4 score is a scoring system used to estimate the amount of scarring in the liver. It is based on common clinical parameters (age, AST, ALT, and platelets) and has been shown to have the best diagnostic accuracy for advanced fibrosis when compared with other noninvasive clinical scores. Scores are categorized into low (\<1.30), indeterminate (1.30-2.67), or high (\>2.67) risk of fibrosis. The formula for Fib-4 is: (Age \[yr\] x AST \[U/L\]) / ((PLT \[109/L\]) x (ALT \[U/L\])½); there are no minimum or maximum values

Time frame:
Week 12 and Week 36
Reported as:
Mean · score on a scale
Change From Baseline To Week 12 And Week 36 In Fibrosis-4 (Fib-4) Score
score on a scaleMGL-3196Placebo
Week 12-0.03 ± 0.3860.05 ± 0.374
Week 360.02 ± 0.3560.07 ± 0.436
SecondaryChange From Baseline of Thyrotropin at Week 12

Thyrotropin (TSH) was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Mean · mIU/L
Change From Baseline of Thyrotropin at Week 12
mIU/LMGL-3196Placebo
Change From Baseline of Thyrotropin at Week 120.096 ± 0.9136-0.101 ± 0.9742
SecondaryChange From Baseline of Total Thyroxine at Week 12

Total thyroxine (FT4) was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Mean · μg/dL
Change From Baseline of Total Thyroxine at Week 12
μg/dLMGL-3196Placebo
Change From Baseline of Total Thyroxine at Week 12-1.18 ± 0.958-0.07 ± 0.726
SecondaryChange From Baseline of Free Thyroxine at Week 12

Free thyroxine (FT4) was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Mean · ng/dL
Change From Baseline of Free Thyroxine at Week 12
ng/dLMGL-3196Placebo
Change From Baseline of Free Thyroxine at Week 12-0.147 ± 0.11540.001 ± 0.0930
SecondaryChange From Baseline of Total Triiodothyronine at Week 12

Total Triiodothyronine (T3) was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Mean · μg/L
Change From Baseline of Total Triiodothyronine at Week 12
μg/LMGL-3196Placebo
Change From Baseline of Total Triiodothyronine at Week 120.03 ± 0.1890.02 ± 0.236
SecondaryChange From Baseline of Free Triiodothyronine at Week 12

Free triiodothyronine (T3) was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Mean · ng/L
Change From Baseline of Free Triiodothyronine at Week 12
ng/LMGL-3196Placebo
Change From Baseline of Free Triiodothyronine at Week 120.05 ± 0.363-0.02 ± 0.513
SecondaryChange From Baseline of Thyroxine Binding Globulin at Week 12

Thyroxine Binding Globulin was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Mean · mg/L
Change From Baseline of Thyroxine Binding Globulin at Week 12
mg/LMGL-3196Placebo
Change From Baseline of Thyroxine Binding Globulin at Week 12-1.42 ± 3.8590.39 ± 3.522
SecondaryChange From Baseline of Reverse Triiodothyronine Globulin at Week 12

Reverse Triiodothyronine (T3) was assessed at each study visit.

Time frame:
Baseline up to Week 12
Reported as:
Mean · ng/dL
Change From Baseline of Reverse Triiodothyronine Globulin at Week 12
ng/dLMGL-3196Placebo
Change From Baseline of Reverse Triiodothyronine Globulin at Week 12-5.22 ± 5.255-0.96 ± 5.757
SecondaryChange From Baseline of Thyrotropin at Week 36

Tyrotropin (TSH) was assessed at each study visit.

Time frame:
Baseline up to Week 36
Reported as:
Mean · mIU/L
Change From Baseline of Thyrotropin at Week 36
mIU/LMGL-3196Placebo
Change From Baseline of Thyrotropin at Week 360.034 ± 0.97050.043 ± 0.9481
SecondaryChange From Baseline of Total Thyroxine at Week 36

Total thyroxine (FT4), thyrotropin (TSH) was assessed at each study visit.

Time frame:
Baseline up to Week 36
Reported as:
Mean · μg/dL
Change From Baseline of Total Thyroxine at Week 36
μg/dLMGL-3196Placebo
Change From Baseline of Total Thyroxine at Week 36-1.10 ± 1.013-0.17 ± 0.846
SecondaryChange From Baseline of Free Thyroxine Week 36

Total free thyroxine (FT4) was assessed at each study visit.

Time frame:
Baseline up to Week 36
Reported as:
Mean · ng/dL
Change From Baseline of Free Thyroxine Week 36
ng/dLMGL-3196Placebo
Change From Baseline of Free Thyroxine Week 36-0.138 ± 0.1280-0.007 ± 0.1162
SecondaryChange From Baseline of Total Triiodothyronine at Week 36

Total triiodothyronine (T3) was assessed at each study visit.

Time frame:
Baseline up to Week 36
Reported as:
Mean · μg/L
Change From Baseline of Total Triiodothyronine at Week 36
μg/LMGL-3196Placebo
Change From Baseline of Total Triiodothyronine at Week 360.02 ± 0.212-0.2 ± 0.190
SecondaryChange From Baseline of Free Triiodothyronine at Week 36

Free triiodothyronine (T3) was assessed at each study visit.

Time frame:
Baseline up to Week 36
Reported as:
Mean · ng/L
Change From Baseline of Free Triiodothyronine at Week 36
ng/LMGL-3196Placebo
Change From Baseline of Free Triiodothyronine at Week 360.02 ± 0.404-0.02 ± 0.475
SecondaryChange From Baseline of Thyroxine-Binding Globulin at Week 36

Thyroxine-binding globulin (TBG) was assessed at each study visit.

Time frame:
Baseline up to Week 36
Reported as:
Mean · mg/L
Change From Baseline of Thyroxine-Binding Globulin at Week 36
mg/LMGL-3196Placebo
Change From Baseline of Thyroxine-Binding Globulin at Week 36-0.38 ± 4.4111.35 ± 5.639
SecondaryChange From Baseline of Reverse Triiodothyronine at Week 36

Reverse triiodothyronine (T3) was assessed at each study visit.

Time frame:
Baseline up to Week 36
Reported as:
Mean · ng/dL
Change From Baseline of Reverse Triiodothyronine at Week 36
ng/dLMGL-3196Placebo
Change From Baseline of Reverse Triiodothyronine at Week 36-4.41 ± 5.582-1.04 ± 5.493

Adverse events

Collected over Screening up to Week 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MGL-3196 Main Study0/84 (0%)5/84 (6%)73/84 (86.9%)
Placebo Main Study0/41 (0%)2/41 (4.9%)28/41 (68.3%)
Extension Study0/31 (0%)0/31 (0%)6/31 (19.4%)
Most frequent serious events
Most frequent serious events
EventMGL-3196 Main StudyPlacebo Main StudyExtension Study
Umbilical herniaGastrointestinal disorders0/841/410/31
Bile duct stonesHepatobiliary disorders0/841/410/31
Clostridium difficile colitisInfections and infestations1/840/410/31
Post procedural haemorrhageInjury, poisoning and procedural complications1/840/410/31
Spinal column stenosisMusculoskeletal and connective tissue disorders1/840/410/31
Cerebrovascular accidentNervous system disorders1/840/410/31
UreterolithiasisRenal and urinary disorders1/840/410/31
Most frequent other events
Showing 10 of 16
Most frequent other events
EventMGL-3196 Main StudyPlacebo Main StudyExtension Study
DiarrhoeaGastrointestinal disorders31/844/412/31
NauseaGastrointestinal disorders17/842/410/31
HeadacheNervous system disorders11/846/410/31
Urinary tract infectionInfections and infestations9/844/410/31
DizzinessNervous system disorders6/844/410/31
FatigueGeneral disorders4/844/410/31
NasopharyngitisInfections and infestations5/842/413/31
Abdominal Pain UpperGastrointestinal disorders7/841/410/31
Abdominal PainGastrointestinal disorders6/843/410/31
Accidental overdoseInjury, poisoning and procedural complications2/843/410/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)MGL-3196PlaceboTotal
Mean51.8 ± 10.3547.3 ± 11.7150.3 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)MGL-3196PlaceboTotal
Female461763
Male382462
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MGL-3196PlaceboTotal
Hispanic or Latino372259
Not Hispanic or Latino471966
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MGL-3196PlaceboTotal
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American112
White8037117
More than one race000
Unknown or Not Reported101
Hepatic Fat Fraction by MRI-PDFF at Screening
Hepatic Fat Fraction by MRI-PDFF at Screening(percentage)MGL-3196PlaceboTotal
Mean20.25 ± 6.84319.63 ± 8.15920.05 ± 7.274
08

Study locations

26 sites
  • Madrigal Research Site
    Dothan, Alabama, United States
  • Madrigal Research Site
    Tucson, Arizona, United States
  • Madrigal Research Site
    Coronado, California, United States
  • Madrigal Research Site
    Los Angeles, California 90057, United States
  • Madrigal Research Site
    Rialto, California, United States
  • Madrigal Research Site
    San Diego, California, United States
  • Madrigal Research Site
    Ventura, California, United States
  • Madrigal Research Site
    Englewood, Colorado, United States
  • Madrigal Research Site
    Boca Raton, Florida, United States
  • Madrigal Research Site
    Lakewood Rch, Florida, United States
  • Madrigal Research Site
    Lauderdale Lakes, Florida, United States
  • Madrigal Research Site
    Miami, Florida, United States
  • Madrigal Research Site
    New Port Richey, Florida, United States
  • Madrigal Research Site
    Kansas City, Kansas, United States
  • Madrigal Research Site
    Monroe, Louisiana, United States
  • Madrigal Research Site
    Baltimore, Maryland, United States
  • Madrigal Research Site
    Jackson, Mississippi 39202, United States
  • Madrigal Research Site
    St Louis, Missouri, United States
  • Madrigal Research Site
    Albuquerque, New Mexico, United States
  • Madrigal Research Site
    New York, New York, United States
  • Madrigal Research Site
    Durham, North Carolina, United States
  • Madrigal Research Site
    Rapid City, South Dakota, United States
  • Madrigal Research Site
    Live Oak, Texas 78233, United States
  • Madrigal Research Site
    San Antonio, Texas, United States
  • Madrigal Research Site
    Charlottesville, Virginia, United States
  • Madrigal Research Site
    Seattle, Washington, United States
09

References and documents

Publications

  • Harrison SA, Ratziu V, Anstee QM, Noureddin M, Sanyal AJ, Schattenberg JM, Bedossa P, Bashir MR, Schneider D, Taub R, Bansal M, Kowdley KV, Younossi ZM, Loomba R. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024 Jan;59(1):51-63. doi: 10.1111/apt.17734. Epub 2023 Oct 2. PubMed 37786277 ↗
  • Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol. 2022 Jun;20(6):1354-1361.e7. doi: 10.1016/j.cgh.2021.07.039. Epub 2021 Jul 27. PubMed 34329774 ↗
  • Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatol Commun. 2021 Jan 4;5(4):573-588. doi: 10.1002/hep4.1657. eCollection 2021 Apr. PubMed 33860116 ↗
  • Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11. PubMed 31727409 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Oct 2017, 12 months.

Results were first posted in Dec 2025, 8 years 1 month after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 12 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2016
First posted
Sep 23, 2016
StartActual
Oct 18, 2016
Primary completionActual
Oct 25, 2017
CompletionActual
Nov 23, 2021
Results first posted
Dec 23, 2025
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02912260
Responsible party
Sponsor
First posted
Sep 23, 2016
Start date
Oct 18, 2016
Primary completion
Oct 25, 2017
Completion
Nov 23, 2021
Results posted
Dec 23, 2025
Last update
Dec 23, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resmetirom

Start the discussion